BGM Group Ltd(BGM) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.16 | Insider Own | 72.42% | Shs Outstand | 180.6M | Perf Week | -1.47% |
| Market Cap | 0.12B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 116.0M | Perf Month | -5.29% |
| Enterprise Value | 0.11B | PEG | - | EPS next Q | - | Inst Own | 0.09% | Short Float | 0.15% | Perf Quarter | -35.14% |
| Income | -0.02B | P/S | 2.42 | EPS this Y | - | Inst Trans | 0.39% | Short Ratio | 0.46 | Perf Half Y | -72.71% |
| Sales | 0.05B | P/B | 0.14 | EPS next 5Y | - | ROA | -6.58% | Short Interest | 0.18M | Perf YTD | -92.53% |
| Book/sh | 1.99 | P/C | 10.04 | EPS past 3/5Y | - | ROE | -7.3% | 52W High | -97.66% ($11.80) | Perf Year | -96.21% |
| Cash/sh | 0.03 | P/FCF | 79.4 | Sales past 3/5Y | -16.38% -5.39% | ROIC | -5.32% | 52W Low | 20.51% ($0.23) | Perf 3Y | -93.08% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 43.63% | Gross Margin | 12.81% | Volatility(W/M) | 10.78% 13.91% | Perf 5Y | -98.62% |
| Dividend TTM | - | EV/Sales | 2.24 | Sales Y/Y TTM | 78.43% | Oper. Margin | -23.42% | ATR (14) | 0.03 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.65 | EPS Q/Q | 58.46% | Profit Margin | -44.22% | RSI (14) | 46.98 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.25 | Sales Q/Q | 69.76% | SMA20 | -1.5% ($0.28) | Beta | 1.85 | Target Price | - |
| Payout | - | Debt/Eq | 0 | Earnings | - | SMA50 | -6.46% ($0.3) | Rel Volume | 0.35 | Prev Close | $0.27 |
| Employees | 471 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -82.35% ($1.59) | Avg Volume(3M) | 0.39M | Price | $0.28 |
| IPO | 2021/1/12 | Option/Short | No/Yes | Trades | 148 | Volume | 137,156 | Change | 0.92% |
Company
BGM is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
💊 BGM Group is a healthcare company listed on the US Nasdaq, building its growth foundation around specialty and generic pharmaceutical businesses. As a micro-cap growth stock seeking to expand its footprint in the pharmaceutical market through enhanced manufacturing capabilities and a broader product portfolio, it is pursuing business diversification to stabilize its revenue structure.
Over the past 1 year, on the lower side
98% below its 1-year high.
BGM has weak earning power
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Holding long would have lost money
Would have changed by -93.1% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 0.1%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
EWX 0.00%
GXC 0.00%
ONEQ 0.00%It ranks #4 in the industry
Based on market cap of $116M.
BGM $116M PER -
TAK $58B PER -
TEVA $42B PER 61.1
HLN $41B PER 19.0
FAQ
What kind of company is BGM?
BGM belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of BGM?
The market cap of BGM is approximately $116M, ranking 4,473 within its sector.
What is the 52-week high and low for BGM?
BGM has recorded a 52-week high of $11.80 and a low of $0.23.
